Chimeric Therapeutics (ASX:CHM) - Executive Chairman and Founder, Paul Hopper
Executive Chairman and Founder, Paul Hopper
Source: Paul Hopper/LinkedIn
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Chimeric Therapeutics’ (CHM) Chief Operating Officer takes the reins as Chief Executive Officer and Managing Director
  • Jennifer Chow will receive a total fixed remuneration of US$550,000 (A$753,000) in her new role, with incentives issued at performance milestones
  • Ms Chow brings more than 20 years of commercial strategy and marketing experience to the role which will support CHM’s development plans
  • Chimeric Therapeutics last traded in the grey at 31.5 cents 

Chimeric Therapeutics (CHM) has seen its Chief Operating Officer take the reins as Chief Executive Officer and Managing Director.

Current COO, Jennifer Chow, will receive a total fixed remuneration of US$550,000 (A$$753,000) in her new role, with incentives issued once performance milestones have been ticked off.

Jennifer Chow has been in the role since November 2020, before which she was Head of Global Marketing, Analytics and Commercial Operations at global CAR T company, Kite Pharmaceuticals.

Ms Chow comes with more than 20 years of commercial strategy and marketing experience, focused on cellular therapy, hematology and oncology.

Furthermore, her appointment will support the company’s plan to develop its oncology pipeline with new and novel cell therapy assets for cancer patients.

Executive Chairman of Chimeric Therapeutics, Paul Hopper, said the company was delighted to appoint Ms Chow as MD and CEO.

“During her time with Chimeric thus far as COO, Jennifer has demonstrated outstanding dedication and leadership while importantly proving to be exceedingly knowledgeable in the field of cell therapy,” Mr Hopper said.

“The team we’ve been able to assemble at Chimeric brings deep scientific and commercial cell therapy expertise to the business and gives us great confidence moving forward under Jenn’s leadership.”

Chimeric Therapeutics was trading in the grey at 31.5 cents at 2:15 pm AEST.

CHM by the numbers
More From The Market Herald
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon

" Little Green Pharma (ASX:LGP) seeks to expand to Greece

Little Green Pharma (ASX:LGP) seeks to expand to Greece

" HeraMED (ASX:HMD) signs “significant milestone” with a Perth hospital

Digital maternity care company HeraMED (ASX:HMD) has hit a "truly significant milestone" with a Perth hospital,…

" ResApp Health (ASX:RAP) signs LOI to launch diagnostic app in the Philippines

ResApp Health (ASX:RAP) smartphone diagnostic test is set to launch in the Philippines through an agreement…

" Emyria (ASX:EMD) set to begin ultra-pure CBD trial

Emyria (ASX:EMD) is set to begin phase one clinical trials of its ultra-pure CBD drug candidate,…